Clinical trials: Chronic Rhinosinusitis With Nasal Polyps(CRSwNP)
- Condition Chronic Rhinosinusitis With Nasal Polyps(CRSwNP)
- Funder type Industry (pharma, biotech, devices)
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Clinical Trial of TQC2731 Injection in Patients With Chronic Sinusitis and Nasal Polyps
TQC2731 injection is a humanized monoclonal antibody that targets Thymic Stromal Lymphopoietin (TSLP), blocks the TSLP pathway, and inhibits the production of downstream cytokines, thereby exerting anti-inflammatory effects.
- Trial name
- NCT07107256
- Testing
- TQC2731 injection
- Where
- 60 sites in China
- Volunteers
- 246 people
- Sponsor
- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)
Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps
Primary Objective: To evaluate the efficacy of dupilumab 300 mg every 2 weeks (q2w) compared to placebo on a background of mometasone furoate nasal spray (MFNS) in reducing nasal congestion (NC)/obstruction severity and…
- Trial name
- SINUS-52 (NCT02898454)
- Testing
- Dupilumab SAR231893 (REGN668), Mometasone furoate nasal spray
- Where
- 123 sites in United States, Argentina and 12 more
- Volunteers
- 448 people
- Sponsor
- Sanofi
Chronic Rhinosinusitis With Nasal Polyps
Dupilumab in Japanese Patients With Chronic Rhinosinusitis With Nasal Polyp (SINUS-M52)
This was a Phase 4, open-label, single-arm, multicenter study to evaluate the efficacy and safety of dupilumab subcutaneous (SC) injection monotherapy in Japanese participants aged 18 or older with CRSwNP that is not adequately…
- Trial name
- NCT05049122
- Testing
- Dupilumab SAR231893
- Where
- Japan
- Volunteers
- 25 people
- Sponsor
- Sanofi
Chronic Rhinosinusitis With Nasal Polyps
An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps
This is a double-blind, parallel-group, Phase 3, 2-arm study that is designed to provide additional safety information, assess the durability of treatment response, and provide additional PK and immunogenicity assessments.
- Trial name
- CEREN-3 (NCT07424144)
- Testing
- Itepekimab (SAR440340)
- Where
- 46 sites in United States, Argentina and 11 more
- Volunteers
- 59 people
- Sponsor
- Sanofi
Severe Asthma, Chronic Rhinosinusitis With Nasal Polyps(CRSwNP)
Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea
The objectives of this study are to describe the incidence of adverse events and the effectiveness of tezepelumab in patients receiving tezepelumab as indicated for severe asthma or CRSwNP in South Korea.
- Trial name
- Tezepelumab (NCT06998095)
- Volunteers
- 210 people
- Sponsor
- AstraZeneca
Chronic Rhinosinusitis With Nasal Polyps
Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study
This is a single-arm extension study to investigate the long-term safety, tolerability, and efficacy of lunsekimig in adult participants with inadequately controlled CRSwNP who have completed a previous lunsekimig CRSwNP clinical…
- Trial name
- ENSEMBLE (NCT06914908)
- Testing
- Lunsekimig, Mometasone furoate nasal spray (MFNS)
- Where
- 24 sites in United States, Argentina and 4 more
- Volunteers
- 71 people
- Sponsor
- Sanofi
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Chronic Rhinosinusitis With Nasal Polyps
This is a multicenter, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy, safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of AK139 injection compared with placebo in…
- Trial name
- NCT07755371
- Testing
- AK139
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Akeso
Chronic Rhinosinusitis With Nasal Polyps, Asthma
EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients
Primary Objective -To evaluate the efficacy of dupilumab compared to omalizumab in reducing the polyp size and improving sense of smell Secondary Objectives To evaluate the efficacy of dupilumab in improving chronic…
- Trial name
- EVEREST (NCT04998604)
- Testing
- Dupilumab, Omalizumab
- Where
- 87 sites in United States, Belgium and 15 more
- Volunteers
- 360 people
- Sponsor
- Sanofi
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP), Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
GB001 in Adult Participants With Chronic Rhinosinusitis
A Phase 2a, randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of GB001 compared with placebo over 16 weeks of treatment in patients…
- Trial name
- NCT03956862
- Testing
- GB001
- Where
- 38 sites in United States, Czechia and 1 more
- Volunteers
- 97 people
- Sponsor
- GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.
Nasal Polyps
A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) in Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
The aim of this study is to assess the efficacy and safety of GSK5784283 administered as add-on maintenance therapy to participants with CRSwNP.
- Trial name
- PERSISTCRSwNP1 (NCT07782970)
- Testing
- GSK5784283, Standard of Care
- Where
- 8 sites in United States, Japan and 1 more
- Volunteers
- 218 people
- Sponsor
- GlaxoSmithKline
Chronic Rhinosinusitis With Nasal Polyps
Tezepelumab CRSwNP Real World Study (CREW Study)
The CREW Study is a non-interventional prospective, observational study in patients with CRSwNP that will evaluate patient-reported outcomes and describe the proportion of participants achieving treatment goals.)
- Trial name
- CREW (NCT07790198)
- Testing
- Tezepelumab
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Chronic Rhinosinusitis With Nasal Polyps
A Study to Investigate the Clinical Outcome and Quality of Life in Chinese Post-operative CRSwNP Patients
This is a prospective, multicenter real-world observational study designed to describe post-operative outcomes, quality of life, disease control, recurrence-related characteristics, economic burden and post-operative treatment…
- Trial name
- PREDICT (NCT07446738)
- Testing
- Other: Routine Clinical Care for CRSwNP
- Where
- 21 sites in China
- Volunteers
- 146 people
- Sponsor
- AstraZeneca
Sinusitis, Nasal Polyps
A Study to Evaluate 611 in Patients With Chronic Rhinosinusitis With Nasal Polyps
This study will evaluate the effect and safety of 611 in patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
- Trial name
- NCT06639295
- Testing
- 611
- Where
- China
- Volunteers
- 243 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Chronic Rhinosinusitis With Nasal Polyps
Regulatory Post-Marketing Surveillance of Xolair® for Chronic Rhinosinusitis With Nasal Polyps
This study aims to evaluate the safety and effectiveness of Xolair® in patients with chronic rhinosinusitis with nasal polyps in routine clinical practice.
- Trial name
- NCT05626257
- Testing
- Xolair
- Where
- 16 sites in South Korea
- Volunteers
- 135 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Rhinosinusitis With Nasal Polyposis
Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)
The primary objectives of the study are: To longitudinally characterize the long-term effectiveness of DUPIXENT® through assessment of patient-reported symptoms, Health-Related Quality of Life (HRQoL) related to Chronic…
- Trial name
- AROMA (NCT04959448)
- Testing
- DUPIXENT®
- Where
- 81 sites in United States, Canada and 4 more
- Volunteers
- 717 people
- Sponsor
- Regeneron Pharmaceuticals
Chronic Rhinosinusitis with Nasal Polyps
The Study of GR1802 in Patients with Chronic Rhinosinusitis with Nasal Polyps
This is a multi-center, randomized, double blind, placebo-controlled study to evaluate the efficacy, safety, PK, PD and immumogenicity of GR1802 injection in comparison to placebo in addition to a background treatment of…
- Trial name
- NCT05873803
- Testing
- GR1802 injection
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Asthma
Retrospective Analysis of Systemic Glucocorticoid Mediated Long-term Effects, Patient Pathways and Economic Burden Across Multiple Indications
Glucocorticoids are important in the treatment of many inflammatory, allergic, immunologic, and malignant disorders. However, the adverse effects of systemic corticosteroids are one of the most common causes of iatrogenic…
- Trial name
- NCT06488703
- Where
- Germany
- Volunteers
- 107,032 people
- Sponsor
- GlaxoSmithKline
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
A Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase II clinical trial. Its primary objective is to explore and preliminarily evaluate the efficacy and safety of LP-003 Injection in the…
- Trial name
- NCT07313917
- Testing
- LP-003 Injection
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Longbio Pharma
Nasal Polyps
Efficacy and Safety of Depemokimab Monotherapy Without Concomitant Use of Intranasal Corticosteroids (INCS) in Japanese Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
This study will evaluate the efficacy and safety of depemokimab (GSK3511294) without concomitant use of Intranasal corticosteroids (INCS) in participants with Chronic rhinosinusitis with nasal polyps (CRSwNP).
- Trial name
- NCT07701967
- Testing
- Depemokimab
- Where
- 10 sites in Japan
- Volunteers
- 28 people
- Sponsor
- GlaxoSmithKline
Nasal Polyps
Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps
This study will evaluate the efficacy and safety of depemokimab (GSK3511294) in participants with Chronic rhinosinusitis with nasal polyps (CRSwNP).
- Trial name
- ANCHOR-1 (NCT05274750)
- Testing
- Depemokimab (GSK3511294)
- Where
- 105 sites in United States, Argentina and 9 more
- Volunteers
- 276 people
- Sponsor
- GlaxoSmithKline